Vanda Pharmaceuticals' NEREUS Receives FDA Approval, Shares Surge 17.5%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 31 2025
0mins
Should l Buy VNDA?
Source: Benzinga
- FDA Approval: Vanda Pharmaceuticals' NEREUS (tradipitant) has received FDA approval for the prevention of motion-induced vomiting in adults, marking a significant advancement in the company's neuropharmaceutical portfolio and is expected to drive future sales growth.
- Stock Surge: Following the FDA approval announcement, Vanda's shares jumped 17.5% to $8.26 in pre-market trading, reflecting strong market confidence in the new drug's potential and likely attracting increased investor interest.
- Market Outlook: The approval of NEREUS not only opens new market opportunities for Vanda Pharmaceuticals but also enhances its market share in the competitive antiemetic drug sector, strengthening the company's long-term profitability prospects.
- Investor Confidence: This FDA approval boosts investor expectations for Vanda's future performance, potentially prompting more institutional investors to reassess their portfolios, further driving the stock price upward.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VNDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VNDA
Wall Street analysts forecast VNDA stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 8.570
Low
7.50
Averages
13.63
High
22.00
Current: 8.570
Low
7.50
Averages
13.63
High
22.00
About VNDA
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vanda Pharmaceuticals Raises Concerns Over FDA's New Guidance on Drug Development
- FDA Guidance Concerns: Vanda Pharmaceuticals expressed serious concerns regarding the FDA's draft guidance released on March 18, 2026, which aims to support New Approach Methodologies (NAMs) but fails to deliver the substantial reforms needed for a shift away from animal testing, potentially impacting drug development efficiency and ethical standards.
- Ethics and Science Balance: While Vanda acknowledges the FDA's commitment to improving human predictivity and ethical standards, the draft guidance does not strike a better balance between regulatory caution and the scientific reforms necessary, which could delay patient access to safer drugs and affect Vanda's leadership in innovative drug development.
- Legal Challenges to Animal Testing: Vanda has a proven track record of advocating for science-driven change, including legal challenges against FDA requirements for prolonged animal studies, such as nine-month dog toxicity tests, highlighting the ethical imperative to minimize animal suffering, particularly in dogs.
- Collaboration and Policy Advocacy: Vanda stands ready to partner with the FDA, HHS, and stakeholders to advance regulatory policies that leverage cutting-edge science, protect patient safety, reduce animal suffering, and align with both ethical and scientific imperatives, aiming to accelerate the drug development process.
See More
Vanda Pharmaceuticals Raises Concerns Over FDA's New Draft Guidance
- Draft Guidance Flaws: Vanda Pharmaceuticals expresses serious concerns regarding the FDA's draft guidance released on March 18, 2026, criticizing its lack of concrete non-animal testing alternatives, absence of real-world examples, and performance benchmarks, which could hinder the adoption of innovative tools and impact drug development efficiency and safety.
- Insufficient Scientific Basis: The draft provides limited scientific references and practical examples of validated New Approach Methodologies (NAMs), failing to offer developers clear benchmarks for success, potentially leading to a lack of confidence in new methods and delaying drug market entry.
- Balancing Ethics and Science: CEO Mihael H. Polymeropoulos emphasizes the need for the FDA to strike a better balance between regulatory caution and scientific reform to ensure patients gain faster access to safer drugs while addressing ethical concerns related to animal testing, particularly in dogs.
- Call for Revision: Vanda urges the FDA to withdraw the current draft and substantially revise it with stronger scientific grounding and specific NAM examples to accelerate drug development and reduce animal suffering, ensuring the effectiveness and human relevance of new methods.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perspectives on these firms.
- EQIX Stock Outlook: Analysts' views on EQIX stock indicate a cautious market sentiment regarding its future performance, although specific ratings were not detailed in the report.
- Market Dynamics Overview: Changes in analyst ratings can significantly influence investor decisions, potentially leading to stock price volatility, prompting investors to closely monitor these developments.
- Access More Information: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, providing comprehensive market insights and investment references.
See More
FDA Grants Hearing for Vanda's Hetlioz Jet Lag Drug
- Hearing Approval: The FDA has granted a public hearing for Vanda Pharmaceuticals regarding its drug Hetlioz (tasimelteon) for jet lag, marking a rare occurrence for the agency and potentially the first in over four decades, indicating a significant scrutiny of the drug approval process.
- Rejection Reasons: In January, the FDA declined to approve the additional indication for Hetlioz, stating that the data submitted did not adequately demonstrate efficacy, which poses challenges for Vanda's market prospects.
- Current Approval Status: Hetlioz is currently approved for non-24-hour sleep-wake disorder and nighttime sleep disturbances associated with Smith-Magenis syndrome, showcasing its potential applications in specific areas.
- Market Reaction: Despite the FDA's approval of the hearing, Vanda's stock fell approximately 4% on Tuesday, reflecting market uncertainty regarding the future development of its drug.
See More
FDA Grants Vanda Hearing on Jet Lag Drug Rejection
- Hearing Approval: On March 2, 2026, the FDA approved Vanda's request for a formal hearing to review the proposed rejection of its supplemental new drug application for Hetlioz for jet lag treatment, marking the first such hearing in over 40 years, which could influence future approval processes.
- Clinical Trial Results: While the FDA acknowledged positive results from Vanda's recent clinical trials, it expressed concerns that the controlled phase-advance protocols used in the studies do not adequately replicate real-world flight conditions, potentially impacting the drug's practical application.
- Historical Rejection Background: Vanda's application for the jet lag indication was first rejected by the FDA in 2019, and a court-ordered re-review in August 2025 criticized the FDA for not adequately engaging with Vanda's evidence, highlighting the complexities and challenges in drug approvals.
- Market Reaction: Retail sentiment around VNDA stock on Stocktwits remained neutral over the past 24 hours, with message volume decreasing from high to low levels, although VNDA stock has gained 66% over the past 12 months, indicating cautious optimism in the market regarding the company's future prospects.
See More
FDA Grants Vanda Hearing on HETLIOZ® Jet Lag Application
- Hearing Approval: The FDA confirmed on March 2, 2026, that it will hold a formal evidentiary hearing to review Vanda's supplemental new drug application (sNDA) refusal for HETLIOZ®, a rare decision in over 40 years, highlighting the FDA's acknowledgment of the legal and scientific issues raised by Vanda.
- Legal Victory: Vanda successfully overturned the FDA's refusal of HETLIOZ® in August 2025, with the court ruling that the FDA inadequately considered Vanda's clinical trial evidence, emphasizing the company's seven-year effort for a fair review process, which could lead to greater transparency in future drug approvals.
- Market Potential: Currently approved for Non-24-Hour Sleep-Wake Disorder, if the sNDA is approved, HETLIOZ® would become the first FDA-approved treatment for jet lag disorder, addressing the needs of millions of travelers worldwide and presenting significant market expansion opportunities.
- Company Vision: Vanda is focused on developing innovative therapies to meet high unmet medical needs, and the progress of this hearing not only recognizes the company's efforts but may also propel its further development in the biopharmaceutical sector, enhancing its position in the industry.
See More
Vanda Pharmaceuticals Raises Concerns Over FDA's New Guidance on Drug Development
- FDA Guidance Concerns: Vanda Pharmaceuticals expressed serious concerns regarding the FDA's draft guidance released on March 18, 2026, which aims to support New Approach Methodologies (NAMs) but fails to deliver the substantial reforms needed for a shift away from animal testing, potentially impacting drug development efficiency and ethical standards.
- Ethics and Science Balance: While Vanda acknowledges the FDA's commitment to improving human predictivity and ethical standards, the draft guidance does not strike a better balance between regulatory caution and the scientific reforms necessary, which could delay patient access to safer drugs and affect Vanda's leadership in innovative drug development.
- Legal Challenges to Animal Testing: Vanda has a proven track record of advocating for science-driven change, including legal challenges against FDA requirements for prolonged animal studies, such as nine-month dog toxicity tests, highlighting the ethical imperative to minimize animal suffering, particularly in dogs.
- Collaboration and Policy Advocacy: Vanda stands ready to partner with the FDA, HHS, and stakeholders to advance regulatory policies that leverage cutting-edge science, protect patient safety, reduce animal suffering, and align with both ethical and scientific imperatives, aiming to accelerate the drug development process.
See More
Vanda Pharmaceuticals Raises Concerns Over FDA's New Draft Guidance
- Draft Guidance Flaws: Vanda Pharmaceuticals expresses serious concerns regarding the FDA's draft guidance released on March 18, 2026, criticizing its lack of concrete non-animal testing alternatives, absence of real-world examples, and performance benchmarks, which could hinder the adoption of innovative tools and impact drug development efficiency and safety.
- Insufficient Scientific Basis: The draft provides limited scientific references and practical examples of validated New Approach Methodologies (NAMs), failing to offer developers clear benchmarks for success, potentially leading to a lack of confidence in new methods and delaying drug market entry.
- Balancing Ethics and Science: CEO Mihael H. Polymeropoulos emphasizes the need for the FDA to strike a better balance between regulatory caution and scientific reform to ensure patients gain faster access to safer drugs while addressing ethical concerns related to animal testing, particularly in dogs.
- Call for Revision: Vanda urges the FDA to withdraw the current draft and substantially revise it with stronger scientific grounding and specific NAM examples to accelerate drug development and reduce animal suffering, ensuring the effectiveness and human relevance of new methods.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perspectives on these firms.
- EQIX Stock Outlook: Analysts' views on EQIX stock indicate a cautious market sentiment regarding its future performance, although specific ratings were not detailed in the report.
- Market Dynamics Overview: Changes in analyst ratings can significantly influence investor decisions, potentially leading to stock price volatility, prompting investors to closely monitor these developments.
- Access More Information: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, providing comprehensive market insights and investment references.
See More
FDA Grants Hearing for Vanda's Hetlioz Jet Lag Drug
- Hearing Approval: The FDA has granted a public hearing for Vanda Pharmaceuticals regarding its drug Hetlioz (tasimelteon) for jet lag, marking a rare occurrence for the agency and potentially the first in over four decades, indicating a significant scrutiny of the drug approval process.
- Rejection Reasons: In January, the FDA declined to approve the additional indication for Hetlioz, stating that the data submitted did not adequately demonstrate efficacy, which poses challenges for Vanda's market prospects.
- Current Approval Status: Hetlioz is currently approved for non-24-hour sleep-wake disorder and nighttime sleep disturbances associated with Smith-Magenis syndrome, showcasing its potential applications in specific areas.
- Market Reaction: Despite the FDA's approval of the hearing, Vanda's stock fell approximately 4% on Tuesday, reflecting market uncertainty regarding the future development of its drug.
See More
FDA Grants Vanda Hearing on Jet Lag Drug Rejection
- Hearing Approval: On March 2, 2026, the FDA approved Vanda's request for a formal hearing to review the proposed rejection of its supplemental new drug application for Hetlioz for jet lag treatment, marking the first such hearing in over 40 years, which could influence future approval processes.
- Clinical Trial Results: While the FDA acknowledged positive results from Vanda's recent clinical trials, it expressed concerns that the controlled phase-advance protocols used in the studies do not adequately replicate real-world flight conditions, potentially impacting the drug's practical application.
- Historical Rejection Background: Vanda's application for the jet lag indication was first rejected by the FDA in 2019, and a court-ordered re-review in August 2025 criticized the FDA for not adequately engaging with Vanda's evidence, highlighting the complexities and challenges in drug approvals.
- Market Reaction: Retail sentiment around VNDA stock on Stocktwits remained neutral over the past 24 hours, with message volume decreasing from high to low levels, although VNDA stock has gained 66% over the past 12 months, indicating cautious optimism in the market regarding the company's future prospects.
See More
FDA Grants Vanda Hearing on HETLIOZ® Jet Lag Application
- Hearing Approval: The FDA confirmed on March 2, 2026, that it will hold a formal evidentiary hearing to review Vanda's supplemental new drug application (sNDA) refusal for HETLIOZ®, a rare decision in over 40 years, highlighting the FDA's acknowledgment of the legal and scientific issues raised by Vanda.
- Legal Victory: Vanda successfully overturned the FDA's refusal of HETLIOZ® in August 2025, with the court ruling that the FDA inadequately considered Vanda's clinical trial evidence, emphasizing the company's seven-year effort for a fair review process, which could lead to greater transparency in future drug approvals.
- Market Potential: Currently approved for Non-24-Hour Sleep-Wake Disorder, if the sNDA is approved, HETLIOZ® would become the first FDA-approved treatment for jet lag disorder, addressing the needs of millions of travelers worldwide and presenting significant market expansion opportunities.
- Company Vision: Vanda is focused on developing innovative therapies to meet high unmet medical needs, and the progress of this hearing not only recognizes the company's efforts but may also propel its further development in the biopharmaceutical sector, enhancing its position in the industry.
See More
